Consolidated Statements of Operations (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenue	$ 102,000	$ 104,000
Operating expenses
Research and development	972,000	1,011,000
General and administrative	1,397,000	1,627,000
Total operating expenses	2,369,000	2,638,000
Loss from operations	(2,267,000)	(2,534,000)
Other expense
Loss on warrant and derivative liabilities	(11,795,000)	(8,773,000)
Other expense	(431,000)	0
Total other expense	(12,226,000)	(8,773,000)
Net loss	(14,493,000)	(11,307,000)
Accretion of Series B redeemable convertible preferred stock	(338,000)	(314,000)
Net loss attributable to common stockholders	$ (14,831,000)	$ (11,621,000)
Per share information:
Net loss per share of common stock - basic & diluted (in dollar per share)	$ (0.07)	$ (0.06)
Weighted average number of shares of common stock outstanding - basic & diluted (in shares)	212,290,406	182,535,562